The gospel BMS sulphate Azanavir capsule for HIV patients in China is expected to be the first

Azanavir is an HIV-1 protease inhibitor that selectively inhibits the specific processing of viruses Gag and Gag-Pol polyproteins in HIV-1 infected cells, thereby blocking the formation of mature viral bodies and is used in combination with other antiretroviral drugs to treat HIV-1 infectionThe drug was developed by Novartis, Switzerland, and subsequently licensed to BMS, approved in the United States in June 2003, in Japan in December 2003, in Europe in March 2004 (the product is called Reyataz ®) and approved in the country in 2005 (the product is called Reiato ®)Azanave, with its daily administration of the effects of small side effects on fat metabolism, low resistance to drugs, and no cross-resistance with other protease inhibitors, has been widely recognized by doctors and patients, data show that in 2007 its global sales exceeded $1 billion, can be described as a bombshell productSales have declined in recent years as other TREATMENTS for HIV have fallen to just $740 million in 2017, but are still among the top 500 globalsalessulphate Azanave has been in a position of sole importance since it was approved for listing in China in 2005, although its patents in China have expired (the expiry date of the sulphate azanave in China is April 14, 2017), and no other company has filed clinical trials or listing applications for similar productsAzanavir is included in the list of drugs for the expiration, termination, invalidity and absence of an imitation application published by CDE at the end of 2018The publication of the list is intended to guide the development and production of generic drugs and improve the accessibility of drug use by the publicThe application for azanave to be declared in China means that the exclusive variety will finally welcome a second similar product in Chinaabout Anjouta Pharmaceuticals Taizhou Co., LtdAnjouta Pharmaceuticals Taizhou Co., Ltdis an acompany founded by Anjouta India headquarters in Taizhou with an investment of US$100 million, and in July 2018, the opening ceremony of the Taizhou project of Anjouta PharmaceuticalS athin is held in China Pharmaceutical CityAnnouncement shows: the project land area of about 97 acres, built all up to the post-partum, the annual production of 3.5 billion tablets, an annual output of 500 million capsulesFactory in accordance with China GMP, the European Union GMP and the United States cGMP standard construction, after production products will be sold to developed countries in Europe and the United States and the domestic market, annual sales will exceed 2 billion yuanin fact, in addition to submitting the listing application of the sulphate Azanave capsule, Anjouta Pharmaceutical Taizhou Co., Ltdin the second half of this year also declared the listing application of the four products of finaea mine tablets, benzoic acid chlorpyrifos tablets, hydrochlorida grosite sulfate tablets, and Engre net tabletsThese products are all subject to category 5.2 applications for import, which means that Anovita Pharmaceuticals is accelerating the introduction of more of its products to China for more patients in needthe author looked up data to find that its investor - Anjowita India headquarters is a large multinational company, is India's second largest pharmaceutical listed companies, in 2017 alone, there are 350 U.S generic drug applications approved, more than all Chinese pharmaceutical companies in the United States approved the sum, its preparations in the U.S market sales of $2.6 billion, API global sales ranked first, in the pharmaceutical industry ranked first in the pharmaceutical field References: .